Thanks @WIRED @emilylmullin for speaking with our CEO Sean Ainsworth about the first engineered B cell therapy dosed in human trials: 🧬🧬🧬 https://t.co/NUzn8YFKIC

We’re excited to announce our presentation at @WORLDSymposia 2024 Conference, held in San Diego, February 4-9. WORLDSymposium is the largest international gathering of lysosomal disease researchers. Read the full release: https://t.co/nqP55LjHoJ

.@DDWJournal covers our recent first patient dosed using the world’s first engineered B cell therapy. 🧬🧬🧬 https://t.co/QKTyv6Vfrb

.@TrialsArena covers our first patient dosed in #MPS1: https://t.co/tTm7Wmr20e

A trial by Seattle-based Immusoft, a biotech company, said it is the first to genetically engineer B cells and test them in a patient, Wired reported Dec. 15.

CIRM is proud to support @immusoft's groundbreaking B cell therapy trial for MPS I and other diseases. "Our goal is always to move the most promising research forward as fast as we can,” said Dr. Abla Creasey, VP of Therapeutics Development at CIRM. https://t.co/9yX6e05Jpi

Thanks @Inside_PM for covering our first patient dosed news! https://t.co/UQdypwu34e

@emilylmullin, from @WIRED, writes:  "@immusoft announced that its scientists have genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease. It’s the first time engineered B cells have been tested in a person."

.@FierceBiotech covers our first patient dosed for the world’s first engineered B cell therapy. 🧬🧬🧬 https://t.co/y2KmxqjZ6U

Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge. https://t.co/WCW7BvE1jt

Immusoft Begins Clinical Trial of Autologous B-Cell Therapy in Mucopolysaccharidosis Type I. ISP-001, which Immusoft developed using its Immune System Programming platform, aims to reprogram patients' B cells so they keep producing alpha-L-iduronidase.

Engineering B-cells: First in human trial in patient with mucopolysaccharidosis type I Ex vivo B-cell gene engineering to produce missing enzyme by @immusoft https://t.co/k8l7xhKoEr

The Westcott family first invested in @immusoft in 2013 when the idea of genetically engineering B-cells (antibody) was just that…an idea. Ten years later, they have dosed their first patient. One day this technology could change millions of lives. We are proud to have played

Immusoft Administers the First Engineered B Cell in a Human Clinical Trial https://t.co/VlIJBbLgQZ

Great companies, in great company! Honored for Aurion to share BioFuture Stage with @endpts @leileiwuu, Sean Ainsworth @Immusoft, Christine Silverstein @ExcisionBio, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.

At this year's @ASGCTherapy annual meeting, engineered B cells are shining 🤩 Beautiful abstracts from @PaulaUSC Matthew Porteus, Jennifer Adair, @JustinTaylorLab , @HPKiem , Richard James and David Rawlings, @immusoft and @bebiopharma

M&A #news ~@immusoft acquires exclusive, worldwide rights to @UMNews's #IP for #genome edited primary B Cells ~#BiminiHealthTech acquires exclusive license to #accellular dermal matrix product portfolio ~@Mindstrong sells #tech assets to @SonderMind

Excited to announce we’ve acquired the exclusive worldwide rights to IP for #genomeediting technology for primary B cells. 🧬🧬🧬 Read the full release: https://t.co/ueeGPJlmR0

Genome-editing of primary B cells is becoming increasingly important in this space. It’s exciting to be a scientific advisor to Immusoft, the leader in engineered B cells. @eqxfund @immusoft #proudinvestor

@immusoft secures $ 8M from @CIRMnews to advance the engineered B cell clinical program. The funds will help to initiate a clinical trial for ISP-001, an engineered autologous B-cell therapy intended for the treatment of mucopolysaccharidosis type I. https://t.co/By5GtDx6Rk